Cardioprotection of Ischemic Myocardium

Cover Page

Abstract


Aim. Cardioprotective effect of precursors in the synthesis of the uridine-5ʼ-diphosphate (UDP) – the mitochondrial ATP-dependent potassium channels (mitoKATP channels) endogenous activator – uridine and uridine-5ʼ-monophosphate (UMP) and the relation between there mechanism of action and activity of mitoKATP channels were studied.

Methods. The experiments were performed on the male Wistar rats weighing 300-350 g. Acute myocardial ische mia (MI) lasting 60 min was produced by occlusion of the descending branch of the left coronary artery (LCA) under artificial pulmonary ventilation. Animals were anesthetized with sodium ethaminal (50 mg/kg). Uridine or UMP in the dose of 30 mg/kg was injected intravenously 5 min prior to LCA occlusion. A selective blocker of these channels 5-hydroxydecanoate (5-HD, 5 mg/kg intravenously 5 min prior to injection of uridine or UMP) was used to detect the involvement of mitoKATP channels in the effects of drugs. ATP and creatine phosphate (CP) was determined in the heart homogenates. The intensity of lipid peroxidation (LPO) was estimated by the content of lipid hydroperoxides (LHP) and the state of the antioxidant system (AOS) by superoxidedismutase (SOD) activity and the reduced glutathione (GH) content.

Results. Occlusion of the LCA during 60 min led to the decrease of ATP and CP content in the myocardium by 35% and 59% respectively. At the same time changes in LPO and AOS were observed. The amount of LHP increased by 97%, the activity of SOD was reduced by 28% and the content of GH decreased by 30%. Uridine and UMP given 5 minutes prior to LCA occlusion prevented the development of these metabolic disorders in the ischemic myocardium. Selective blocker of mitoKATP channels 5-HD eliminated the protective effect of both drugs.

Conclusion. Uridin and UMP have the evident cardioprotective effect in the acute MI, stabili zing the miocardium energy metabolism, preventing the AOS function depression and excessive activation of LPO. The mechanism of protective action of the drugs is associated with the activation of mitoKATP channels.


Valentina V. Bulion

Institute of Experimental Medicine

Author for correspondence.
Email: vbulion@mail.ru

Russian Federation, St. Petersburg

PhD, Senior Reasercher, S.V. Anichkov Department of Neuropharmacology

Irina B. Krylova

Institute of Experimental Medicine

Email: irinakrylova@mail.ru

Russian Federation, St. Petersburg

PhD, Senior Reasercher, S.V. Anichkov Department of Neuropharmacology

Elena N. Selina

Institute of Experimental Medicine

Email: vbulion@mail.ru

Russian Federation, St. Petersburg

Reasercher, S.V. Anichkov Department of Neuropharmacology

  1. Арутюнян А.В., Дубинина Е.Е., Зыбина Н.Н. Методы оценки свободнорадикального окисления и антиоксидантной системы организма: методические рекомендации / Под ред. В.Х. Хавинсона. - СПб.: Фолиант, 2000. [Arutyunyan AV, Dubinina EE. Zybina NN. Metody otsenki svobodnoradikal’nogo okisleniya i antioksidantnoy sistemy organizma: metodicheskie rekomendatsii. Ed by V.K. Khavinson. Saint Petersburg: Foliant; 2000. (In Russ.)]
  2. Белослудцева Н.В., Крылова И.Б., Бульон В.В., и др. Уридин как потенциальное средство предупреждения и лечения острого инфаркта миокарда. Исследование механизма его антигипоксического действия // Митохондриальные поры, каналы и устойчивость клеток к повреждающим воздействиям / Под ред. В.С. Акатова, Дж.Дж. Лемастерса. - Пущино: SynchroBook, 2016. - С. 49-71. [Belosludtseva NV, Krylova IB, Bul’on VV, et al. Uridin kak potentsial’noe sredstvo preduprezhdeniya i lecheniya ostrogo infarkta miokarda. Issledovanie mekhanizma ego antigipoksicheskogo deystviya. In: Mitokhondrial’nye pory, kanaly i ustoychivost’ kletok k povrezhdayushchim vozdeystviyam. Ed by V.S. Akatov, J.J. Lemasters. Pushchino: SynchroBook; 2016. p. 49-71. (In Russ.)]
  3. Галенко-Ярошевский П.А., Гацура В.В. Экспериментальные аспекты оптимизации фармакотерапии острой ишемии миокарда. - М.: Медицина, 2001. [Galenko-Yaroshevskiy PA, Gatsura VV. Eksperimental’nye aspekty optimizatsii farmakoterapii ostroy ishemii miokarda. Moscow: Meditsina; 2001. (In Russ.)]
  4. Гампер Н.Л., Саар В.Г., Королева Е.М., и др. Определение свободных нуклеотидов в тканевых, клеточных и митохондриальных экстрактах методом микроколоночной высокоэффективной жидкостной хроматографии // Журнал эволюционной биохимии и физиологии. - 1998. - Т. 34. - № 2. - С. 178-182. [Gamper NL, Saar VG, Koroleva EM, et al. The determination of free nucleotides in tissue, cellular and mitochondrial extracts by microcolumn high-performance liquid chromatography. Zh Evol Biokhim Fiziol. 1998;34(2):178-182. (In Russ.)]
  5. Голиков А.П., Михин В.П., Полумисков В.Ю., и др. Эффективность цитопротектора мексикора в неотложной кардиологии // Терапевтический архив. - 2004. - Т. 76. - № 4. - С. 60-65. [Golikov AP, Mikhin VP, Polumiskov VY, et al. Efficacy of cytoprotective agent mexicor in urgent cardiology. Ter Arkh. 2004;76(4):60-65. (In Russ.)]
  6. Голиков А.П., Давыдов Б.В., Руднев Д.В., и др. Влияние мексикора на окислительный стресс при остром инфаркте миокарда // Кардиология. - 2005. - Т. 45. - № 7. - С. 21-26. [Golikov AP, Davydov BV, Rudnev DV, et al. Effect of mexicor on oxidative stress in acute myocardial infarction. Cardiology. 2005;45(7):21-26. (In Russ.)]
  7. Зарубина И.В., Шабанов П.Д. Молекулярная фармакология антигипоксантов. - СПб.: Издательство Н-Л, 2004. [Zarubina IV, Shabanov PD. Molekulyarnaya farmakologiya antigipoksantov. Saint Petersburg: Izdatel’stvo N-L; 2004. (In Russ.)]
  8. Каленикова Е.И., Токарева О.Г., Куляк О.Ю., и др. Сравнение кардиопротекторной эффективности коэнзима Q10 и мексикора при экспериментальной ишемии миокарда // Экспериментальная и клиническая фармакология. - 2015. - Т. 78. - № 6. - С. 12-14. [Kalenikova EI, Tokareva OG, Kulyak OY, et al. Comparative Cardioprotective Efficacy of Coenzyme Q10 and Mexicor in Experimental Model of Myocardial Infarction in Rats. Experimental and clinical pharmacology. 2015;78(6):12-14. (In Russ.)] doi: 10.30906/0869-2092-2015-78-6-12-14.
  9. Костюченко А.Л., Семиголовский Н.Ю. Современные реальности клинического применения антигипоксантов // ФАРМиндекс: практик. - 2002. - № 3. - С. 102-122. [Kostyuchenko AL, Semigolovskiy NY. Sovremennye real’nosti klinicheskogo primeneniya antigipoksantov. FARMindeks: praktik. 2002;(3):102-122. (In Russ.)]
  10. Кукес В.Г., Жернакова Н.И., Горбач Т.В., и др. Эффективность триметазидина при экспериментальной ишемической болезни сердца в возрастном аспекте // Экспериментальная и клиническая фармакология. - 2013. - Т. 76 - № 2. - С. 9-12. [Kukes VG, Zhernakova NI, Gorbach TV, et al. Efficiency of Trimetazidine Treatment of Experimental Ischemic Heart Disease in Age Aspect. Experimental and clinical pharmacology. 2013;76(2):9-12. (In Russ.)]. doi: 10.30906/0869-2092-2013-76-2-9-12.
  11. Кукес В. Г., Жернакова Н.И., Горбач Т.В., и др. Эффективность милдроната при экспериментальной ишемии миокарда у крыс разного возраста // Вестник Pоссийской академии медицинских наук. - 2013. - № 1. - С. 42-46. [Kukes VG, Zhernakova NI, Gorbach TV, et al. Efficiency of mildronate in rats of different age with experimental-induced myocardial ischemia. Annals of the Russian Academy of Medical Sciences. 2013;(1):42-46. (In Russ.)]
  12. Миронова Г.Д., Качаева Е.В., Крылова И.Б., и др. Митохондриальный АТФ-зависимый калиевый канал. Роль канала в защите сердца от ишемии // Вестник Российской академии медицинских наук. - 2007. - № 2. - С. 44-50. [Mironova GD, Kachaeva EV, Krylova IB, et al. Mitochondrial ATP-dependent potassium channel. The role of the channel in protection of the heart against ischemia. Annals of the Russian Academy of Medical Sciences. 2007;(2):44-50. (In Russ.)]
  13. Dambrova M, Makrecka-Kuka M, Vilskersts R, et al. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacol Res. 2016;113(PtB):771-780. doi: 10.1016/j.phrs.2016.01.019.
  14. Foster MN, Coetzee WA. KATP Channels in the Cardiovascular System. Physiol Rev. 2016;96(1):177-252. doi: 10.1152/physrev.00003.2015.
  15. Sato T, Marban E. The role of mitochondrial K(ATP) channels in cardioprotection. Basic Res Cardiol. 2000;95(4):285-289. doi: 10.1007/s003950070047.
  16. Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci. 2005;1047:248-258. doi: 10.1196/annals.1341.022.
  17. Jaimes R, 3rd, Kuzmiak-Glancy S, Brooks DM, et al. Functional response of the isolated, perfused normoxic heart to pyruvate dehydrogenase activation by dichloroacetate and pyruvate. Pflugers Arch. 2016;468(1):131-142. doi: 10.1007/s00424-015-1717-1.
  18. Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 2001;12(Suppl.1):S8-11.
  19. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93(3):e33-37. doi: 10.1161/01.RES.0000086964.07404.A5.
  20. Parang P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J Cardiovasc Pharmacol Ther. 2005;10(4):217-223. doi: 10.1177/107424840501000402.
  21. Sakamoto M, Takeshige K, Yasui H, Tokunaga K. Cardioprotective effect of succinate against ischemia/reperfusion injury. Surg Today. 1998;28(5):522-528. doi: 10.1007/s005950050177.
  22. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33(2):243-257. doi: 10.1016/S0008-6363(96)00245-3.

Views

Abstract - 176

PDF (Russian) - 81

Cited-By


CrossRef     1 citations

  • Yagudin TA, Shabanova AT, Liu H. Novel Aspects of Cardiac Ischemia and Reperfusion Injury Mechanisms. Creative surgery and oncology. 2019;8(3):216. doi: 10.24060/2076-3093-2018-8-3-216-224

PlumX


Copyright (c) 2018 Bulion V.V., Krylova I.B., Selina E.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.